Summary
Vertex Pharmaceuticals (VRTX) announced significant changes in its executive leadership and a new compensation plan through an 8-K filing dated February 9, 2005. The company entered into a severance agreement with its President, Dr. Vicki Sato, whose employment will conclude on May 11, 2005. Under the agreement, Dr. Sato will receive 18 months of salary and bonus, along with accelerated vesting of her stock options and restricted stock. Concurrently, Vertex is strengthening its strategic and corporate development team with the appointment of Dr. Victor Hartmann as Executive Vice President, effective February 15, 2005. Dr. Hartmann's compensation package includes a base salary, sign-on bonus, and substantial equity awards, including stock options and restricted stock with specific vesting schedules. Additionally, the company adopted a new Employee Compensation Plan designed to align executive and employee compensation with company performance, including base salary, performance bonuses, and equity grants for 2005, with 2004 bonuses ranging from 0% to 55% of base salary.
Key Highlights
- 1President Vicki Sato to depart on May 11, 2005, with an 18-month severance package including accelerated equity vesting.
- 2Appointment of Dr. Victor Hartmann as Executive Vice President of Strategic and Corporate Development.
- 3Dr. Hartmann's compensation includes a $429,000 base salary, a $150,000 sign-on bonus, and significant stock options and restricted stock grants.
- 4New Employee Compensation Plan adopted for 2005, covering base salary, performance bonuses, and equity grants, linking compensation to corporate goals.
- 52004 performance bonuses awarded ranged from 0% to 55% of base salary for officers and employees.
- 6Dr. Hartmann brings extensive experience in business development and licensing from Novartis Pharma AG.
- 7The severance agreement with Dr. Sato includes mutual releases of claims between her and the company.